Testing Data
(Staining of human peripheral blood lymphocytes with Mouse anti Human CD299: Azide Free (MBS210211))
Mouse CD229 Monoclonal Antibody | anti-CD229 antibody
MOUSE ANTI HUMAN CD229:RPE
Flow Cytometry: Maximum Dilution: Neat
Perservative Stabilisers
Shelf Life: 12 months from date of reconstitution.
Testing Data
(Staining of human peripheral blood lymphocytes with Mouse anti Human CD299: Azide Free (MBS210211))
Testing Data
(Staining of human peripheral blood lymphocytes with Mouse anti Human CD299: Azide Free (MBS210211))
Testing Data
(Published customer image: Correlation between SLAMF3 expression and HCC cell proliferation.(A) Effects of the introduction of specific siRNAs on SLAMF3 expression in Huh-7 cells. Cells were transiently transfected with a scrambled siRNA (Sc) or one of two pre-designed anti-SLAMF3 siRNAs (referred to as #2 and # 3); SLAMF3 expression was measured by Western blot analysis (anti-SLAMF3, K12). One representative of two independent experiments is shown. (B) siRNA-treated Huh-7 cells were cultured and proliferation was assayed in a Trypan blue exclusion test after 48 h. Proliferation is presented as the mean number of viable cells +/- SD (n = 5; statistical significance: ***p)
Testing Data
(Published customer image: Correlation between SLAMF3 expression and HCC cell proliferation.(A) Effects of the introduction of specific siRNAs on SLAMF3 expression in Huh-7 cells. Cells were transiently transfected with a scrambled siRNA (Sc) or one of two pre-designed anti-SLAMF3 siRNAs (referred to as #2 and # 3); SLAMF3 expression was measured by Western blot analysis (anti-SLAMF3, K12). One representative of two independent experiments is shown. (B) siRNA-treated Huh-7 cells were cultured and proliferation was assayed in a Trypan blue exclusion test after 48 h. Proliferation is presented as the mean number of viable cells +/- SD (n = 5; statistical significance: ***p)
Testing Data
(Staining of human peripheral blood lymphocytes with Mouse anti Human CD229 : RPE)
Testing Data
(Staining of human peripheral blood lymphocytes with Mouse anti Human CD229 : RPE)
Testing Data
(Published customer image SLAMF3 over-expression increases hepatocyte permissiveness to HCV. Huh-7 cells were transfected with empty vector pBud (mock) or human SLAMF3 (to yield Huh-7+ cells) and incubated with HCVcc. (A) SLAMF3 expression was analyzed by flow cytometry (HLy9.1.25 clone) and (B) visualized by confocal microscopy in one out of three experiment. Unshaded histograms show the isotype-matched control (Co) and shaded histograms show SLAMF3 expression). (C, D, E) Infection was assessed at 4 and 72 h p.i. as the number of FFUs and (F and G) by flow cytometry analysis; (C) intracellular E2 (stained red) were measured at 4 h and 72 h p.i. Green staining corresponds to the SLAMF3 expression. One of three representatives independent experiments is shown. (D) The HCV permissiveness of Huh-7 mock and Huh-7+ cells was evaluated in terms of the number of FFUs based on intracellular E2 viral protein staining and (E) fluorescent microscopy analysis (mean of five experiments; error bars: SD; *p)
Testing Data
(Published customer image SLAMF3 over-expression increases hepatocyte permissiveness to HCV. Huh-7 cells were transfected with empty vector pBud (mock) or human SLAMF3 (to yield Huh-7+ cells) and incubated with HCVcc. (A) SLAMF3 expression was analyzed by flow cytometry (HLy9.1.25 clone) and (B) visualized by confocal microscopy in one out of three experiment. Unshaded histograms show the isotype-matched control (Co) and shaded histograms show SLAMF3 expression). (C, D, E) Infection was assessed at 4 and 72 h p.i. as the number of FFUs and (F and G) by flow cytometry analysis; (C) intracellular E2 (stained red) were measured at 4 h and 72 h p.i. Green staining corresponds to the SLAMF3 expression. One of three representatives independent experiments is shown. (D) The HCV permissiveness of Huh-7 mock and Huh-7+ cells was evaluated in terms of the number of FFUs based on intracellular E2 viral protein staining and (E) fluorescent microscopy analysis (mean of five experiments; error bars: SD; *p)
Testing Data
(Published customer image: SLAMF3 expression is repressed in tumour cells from ten resected HCC patients. (A) SLAMF3 mRNA expression was analysed in hepatocytes from resected HCC patients. Specific amplification of SLAMF3 mRNAs using PCR (representative patients #2, #7 and #12) and quantitative PCR in tumour tissues (T) and peritumoral tissues (pT) presented separately (B) and as median (**p)
Testing Data
(Published customer image: SLAMF3 expression is repressed in tumour cells from ten resected HCC patients. (A) SLAMF3 mRNA expression was analysed in hepatocytes from resected HCC patients. Specific amplification of SLAMF3 mRNAs using PCR (representative patients #2, #7 and #12) and quantitative PCR in tumour tissues (T) and peritumoral tissues (pT) presented separately (B) and as median (**p)
Testing Data
(Published customer image: Restoration of SLAMF3 expression in HCC cells inhibits MAPK ERK1/2, JNK and mTOR pathways and induces caspase-dependent apoptosis.(A) SLAMF3 expression was confirmed by Western blot analysis in SLAMF3-over-expressing Huh-7 and mock cells at 48 h post-transfection. ERK1/2, JNK, p38, AKT and mTOR proteins were detected as controls. The activation levels of MAPK ERK1/2 (Thr 202/Tyr 204), JNK (Thr 183/Tyr 185), p38 (Thr 180/Tyr 183), PI3K (p85/p110 Thr 467/Tyr 199), AKT (Ser 473, Thr 308) and mTOR (Ser 2448, Ser 2481) are represented. One of three representative experiments is shown here. (B) The results of an active caspase assay based on cell-permeable fluorochrome inhibitor of caspases (FLICA). Caspase activity was evaluated in HCC cells (Huh-7 and HepG2 lines) at the indicated times after the ectopic introduction of SLAMF3 vector. Caspase activity is shown in the SLAMF3neg subpopulation (in white) and the SLAMF3pos (overlaid in grey) subpopulation from one representative of two independent experiments.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data
(Published customer image: Restoration of SLAMF3 expression in HCC cells inhibits MAPK ERK1/2, JNK and mTOR pathways and induces caspase-dependent apoptosis.(A) SLAMF3 expression was confirmed by Western blot analysis in SLAMF3-over-expressing Huh-7 and mock cells at 48 h post-transfection. ERK1/2, JNK, p38, AKT and mTOR proteins were detected as controls. The activation levels of MAPK ERK1/2 (Thr 202/Tyr 204), JNK (Thr 183/Tyr 185), p38 (Thr 180/Tyr 183), PI3K (p85/p110 Thr 467/Tyr 199), AKT (Ser 473, Thr 308) and mTOR (Ser 2448, Ser 2481) are represented. One of three representative experiments is shown here. (B) The results of an active caspase assay based on cell-permeable fluorochrome inhibitor of caspases (FLICA). Caspase activity was evaluated in HCC cells (Huh-7 and HepG2 lines) at the indicated times after the ectopic introduction of SLAMF3 vector. Caspase activity is shown in the SLAMF3neg subpopulation (in white) and the SLAMF3pos (overlaid in grey) subpopulation from one representative of two independent experiments.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data
(Published customer image: Expression of SLAMF3 assessed by flow cytometry analysis after transfection with vector coding for SLAMF3 or an empty vector (Mock) in Huh-7 and HepG2 cells. SLAMF3 staining (in grey) is overlaid by negative control (in white). One of four independent experiments is shown. doi:10.1371/journal.pone.0082918.s002From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data
(Published customer image: Expression of SLAMF3 assessed by flow cytometry analysis after transfection with vector coding for SLAMF3 or an empty vector (Mock) in Huh-7 and HepG2 cells. SLAMF3 staining (in grey) is overlaid by negative control (in white). One of four independent experiments is shown. doi:10.1371/journal.pone.0082918.s002From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data
(Published customer image: Expression of SLAM-R family by HHPHs and Huh-7 and HepG2 human HCC cell lines. SLAM-Rs were stained with specific antibodies against SLAMF1 (CD150), SLAMF2 (CD84), SLAMF4 (CD224) and SLAMF6 (NTBA) (grey) or with matched isotype controls (empty). One of four independent experiments is shown.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data
(Published customer image: Expression of SLAM-R family by HHPHs and Huh-7 and HepG2 human HCC cell lines. SLAM-Rs were stained with specific antibodies against SLAMF1 (CD150), SLAMF2 (CD84), SLAMF4 (CD224) and SLAMF6 (NTBA) (grey) or with matched isotype controls (empty). One of four independent experiments is shown.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data
(Published customer image: Effect of SLAMF3 expression on the organization of the actin cytoskeleton. Cells (Huh-7) were stained with phalloidin (rhodamine, red) and anti-SLAMF3 (FITC, green) and SLAMF3 positive (Huh-7-SLAMF3pos) and SLAMF3-negative (Huh-7-SLAMF3pos) cells were examined under the microscope. One representative of two independent experiments is shown.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data
(Published customer image: Effect of SLAMF3 expression on the organization of the actin cytoskeleton. Cells (Huh-7) were stained with phalloidin (rhodamine, red) and anti-SLAMF3 (FITC, green) and SLAMF3 positive (Huh-7-SLAMF3pos) and SLAMF3-negative (Huh-7-SLAMF3pos) cells were examined under the microscope. One representative of two independent experiments is shown.From: Marcq I, Nyga R, Cartier F, Amrathlal RS, Ossart C, et al. (2013) Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE 8(12): e82918.)
Testing Data
(Published customer imageSLAMF3 blockade in human hepatocytes is associated with lower susceptibility to HCV. (A) SLAMF3 was stained in primary human hepatocytes (PHHs) and cells from the Huh-7 human hepatoma cell line with a specific antibody (HLy9.1.25 clone; grey) and an isotype-matched control (empty). One of four independent experiments is shown. Huh-7 cells were transfected with scrambled control (sc) siRNA or three specific siRNAs (#1, #2 and #3) targeting SLAMF3, prior to infection with HCVcc; siRNA efficiency was checked by quantifying SLAMF3 mRNA (B) and the CD81 expression level (C) by flow cytometry analysis at 48 h post-transfection. Results are presented as the mean +/-SD (n = 3). Intracellular viral RNA was quantified at 72 h p.i. (D) and the infection was measured at 72 h p.i. by focus-forming units FFUs counting (E) (as inhibition percent; mean of three independent experiments; error bars: SD. **p)
Testing Data
(Published customer imageSLAMF3 blockade in human hepatocytes is associated with lower susceptibility to HCV. (A) SLAMF3 was stained in primary human hepatocytes (PHHs) and cells from the Huh-7 human hepatoma cell line with a specific antibody (HLy9.1.25 clone; grey) and an isotype-matched control (empty). One of four independent experiments is shown. Huh-7 cells were transfected with scrambled control (sc) siRNA or three specific siRNAs (#1, #2 and #3) targeting SLAMF3, prior to infection with HCVcc; siRNA efficiency was checked by quantifying SLAMF3 mRNA (B) and the CD81 expression level (C) by flow cytometry analysis at 48 h post-transfection. Results are presented as the mean +/-SD (n = 3). Intracellular viral RNA was quantified at 72 h p.i. (D) and the infection was measured at 72 h p.i. by focus-forming units FFUs counting (E) (as inhibition percent; mean of three independent experiments; error bars: SD. **p)
NCBI and Uniprot Product Information
NCBI Description
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A; MIM 300490) (Graham et al., 2006 [PubMed 16365421]).[supplied by OMIM, Mar 2008]
Uniprot Description
CD229: May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. 4 isoforms of the human protein are produced by alternative splicing.
Protein type: Cell surface; Membrane protein, integral
Chromosomal Location of Human Ortholog: 1q23.3
Cellular Component: integral to membrane
Molecular Function: receptor activity
Biological Process: cell adhesion
Research Articles on CD229
Similar Products
Product Notes
The CD229 ly9 (Catalog #AAA213728) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. AAA Biotech's CD229 can be used in a range of immunoassay formats including, but not limited to, Flow cytometry (FC/FACS). Flow Cytometry: Use 10ul of the suggested working dilution to label 106 cells in 100ul or 100ul whole blood. Flow Cytometry: Maximum Dilution: Neat. Researchers should empirically determine the suitability of the CD229 ly9 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "CD229, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
